Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

TABLE 1

Fasting and meal-related results

NN2211 Placebo P
Fasting values
    plasma glucose (mmol/l) 6.9 ± 1.0 8.1 ± 1.0 <0.01
    insulin secretory rate (pmol/min) 179 ± 70 163 ± 66 0.03
    glucagon (pmol/l) 19 ± 4 20 ± 4 NS
Homeostasis model assessment
    HOMA-B 0.56 ± 0.16 0.36 ± 0.12 <0.001
    HOMA-S 3.0 ± 1.3 3.1 ± 1.7 NS
Meal-related AUC1130-1530h
    plasma glucose (mmol · l−1 · h−1) 30.6 ± 2.4 39.9 ± 7.3 <0.001
    plasma glucose (mmol · l−1 · h−1) increment 7.0 ± 2.6 9.6 ± 4.5 0.04
    insulin secretory rate (nmol) 118 ± 32 106 ± 27 NS
    insulin secretory rate (nmol) increment 65 ± 22 45 ± 11 0.03
    glucagon (pmol · l−1 · h−1) 77 ± 18 82 ± 17 0.04
    glucagon (pmol · l−1 · h−1) increment 6 ± 10 6 ± 10 NS
    3-OMG (mg · l−1 · h−1) 400 ± 84 440 ± 70 0.02
  • Mean fasting values and HOMA were calculated from samples obtained at 7 h and 8 h. The meal response was calculated as integrated AUC in absolute values and as increments relative to premeal values (mean of 1115 h and 1130 h) for glucose, ISR, glucagon, and 3-OMG. NS, not significant.

This Article

  1. Diabetes vol. 51 no. 2 424-429